10-Q: Cytta Corp. Q3 2025: Net Income Reversal Amidst Marketable Securities Gain

Sentiment:

Quarterly Report 30 October 2025 5:41 PM

Cytta Corp. reported a significant net income for the nine months ended June 30, 2025, primarily driven by an unrealized gain on marketable securities, despite continued operational losses and a going concern warning.

Delay expectedThe MVP (Minimum Viable Product) versions of the CyttaCOMMS product were terminated, and the server-side architecture is being redesigned to incorporate missing functionality requested by users, delaying its enterprise-level sales program.The CyttaCARES system, while at the trial/MVP stage, requires additional work to reach the MMP (Minimum Marketable Product) stage before live school demonstrations can begin, due to the sensitive nature of the technology.

Capital raiseThe company explicitly states its intention to fund operations through "equity and/or debt financing arrangements."The "going concern" warning highlights the need for additional capital to meet obligations and expand the business.Convertible notes payable were significantly reduced, partly through conversion into RM stock, but the need for future financing remains.

Summary

Net income for the nine months ended June 30, 2025, was $3,368,421, a substantial improvement from a net loss of $3,501,446 for the same period in 2024.
A net loss of $(2,129,260) was reported for the three months ended June 30, 2025, compared to a net loss of $(1,453,777) for the same period in 2024.
Revenues for the nine months ended June 30, 2025, were $2,914, a decrease from $3,243 in the prior year, and $416 for the three months, down from $832.
The company recorded a gross profit loss of $(47,371) for the nine months ended June 30, 2025, due to cost of revenues exceeding minimal sales.
Operating expenses decreased to $1,564,431 for the nine months ended June 30, 2025, from $3,191,909 in the prior year.
Cash balance decreased significantly to $416,892 as of June 30, 2025, from $1,439,835 at September 30, 2024.
Working capital improved to $4,020,187 as of June 30, 2025, primarily driven by the fair value of marketable securities.
Marketable securities, consisting of Reticulate Micro, Inc. (RM) Class A Common Shares, were valued at $4,747,302 at fair value as of June 30, 2025.
An unrealized gain of $5,919,760 on the fair value change of marketable securities was recognized for the nine months ended June 30, 2025, while an unrealized loss of $1,742,138 was recorded for the three months ended June 30, 2025.
Convertible notes payable were reduced from $1,438,950 at September 30, 2024, to $305,950 at June 30, 2025, largely due to conversion into RM stock.
The company formed Cytta Labs Inc. on May 13, 2025, as a venture studio to focus on IP, equity ownership, and long-term value creation.
Material weaknesses in internal controls over financial reporting were identified, including the absence of an Audit Committee and inadequate cash controls.

Sentiment

Score: 4

Explanation: While the nine-month net income is positive due to a large unrealized gain on marketable securities, core operational revenues remain minimal and declining, and the company continues to incur operating losses. The going concern warning persists, and product development delays are noted. The positive working capital is heavily reliant on the volatile valuation of marketable securities.

Positives

Reported a net income of $3,368,421 for the nine months ended June 30, 2025, a significant improvement from a $3,501,446 net loss in the prior year.
Achieved a substantial unrealized gain of $5,919,760 on the fair value change of marketable securities (Reticulate Micro common stock) for the nine-month period.
Significantly reduced convertible notes payable from $1,438,950 to $305,950, primarily through conversion into RM stock, reducing debt burden.
Improved working capital to $4,020,187 as of June 30, 2025, from a deficit position, largely due to the valuation of marketable securities.
Operating expenses decreased by $1,627,478 for the nine months ended June 30, 2025, compared to the prior year, indicating cost management efforts.
Formed Cytta Labs Inc. as a strategic evolution into an innovation holding company focused on IP, equity ownership, and long-term value creation.

Negatives

Continued to report a net loss from operations of $(1,611,802) for the nine months ended June 30, 2025, and $(372,968) for the three months ended June 30, 2025.
Revenue remains very limited at $2,914 for the nine months ended June 30, 2025, and decreased compared to the prior year ($3,243).
Experienced a gross profit loss of $(47,371) for the nine months ended June 30, 2025, due to cost of revenues ($50,285) exceeding minimal revenues.
Cash balance significantly decreased to $416,892 as of June 30, 2025, from $1,439,835 at September 30, 2024.
Incurred an unrealized loss of $1,742,138 on marketable securities for the three months ended June 30, 2025, indicating volatility in the value of its Reticulate Micro holdings.
Accumulated deficit remains high at $33,499,471, raising substantial doubt about the company's ability to continue as a going concern.
Terminated all MVP versions of CyttaCOMMS due to missing functionality requested by users, requiring a server-side architecture redesign and further development to MMP (Minimum Marketable Product) stage.
CyttaCARES system requires additional work to reach the MMP stage before live school demonstrations can begin, due to the sensitive nature of the technology.
Incurred a loss on settlement of debt of $787,637 for the nine months ended June 30, 2025, related to issuing RM stock for debt extinguishment.

Risks

**Going Concern**: The company has an accumulated deficit of $33,499,471 and limited revenues, raising substantial doubt about its ability to continue as a going concern.
**Funding Risk**: The company intends to fund operations through equity and/or debt financing, which may not be sufficient to cover capital expenditures, working capital, and other cash requirements. Inability to raise additional funds will negatively impact business development and financial results.
**Product Development Risk**: The CyttaCOMMS MVP versions were terminated due to missing functionality, requiring redesign and further development to reach the MMP stage. The CyttaCARES system also requires additional work before live demonstrations.
**Marketable Securities Volatility**: The company holds Reticulate Micro common stock, which is subject to fair value changes, as evidenced by a $1,742,138 unrealized loss in the most recent quarter, impacting net income.
**Internal Control Weaknesses**: Material weaknesses in internal controls over financial reporting were identified, including the lack of an Audit Committee and insufficient cash controls, increasing the risk of material misstatement or fraud.
**Concentration of Credit Risk**: Cash and cash equivalents may exceed federally insured limits, exposing the company to credit risk with financial institutions.
**Reliance on Related Parties**: Significant related party transactions for management fees, stock-based compensation, and office rent.

Future Outlook

The company is working to finalize the Minimum Marketable Product (MMP) version of its CyttaCOMMS software (CyttaCOMMS 2.0) for enterprise-level sales, incorporating missing functionality requested from MVP versions. The CyttaCARES system also requires additional work to reach the MMP stage before live school demonstrations can begin due to its sensitive nature. Cytta Labs Inc. was formed as a 'next generation venture studio' and a 'strategic evolution of Cytta Corp into an innovation holding company focused on IP, equity ownership, and long-term value creation.' The company intends to fund operations through equity and/or debt financing arrangements.

Management Comments

"Cytta is in the business of imagineering, developing and securing disruptive technologies."
"Our proprietary CyttaCOMMS incident management software system offers real-time integration of video and audio streams, enabling improved collaboration and providing ongoing, relevant, actionable intelligence."
"Their innovative new product, CyttaCARES, is a game-changer in ensuring the safety and well-being of individuals in educational institutions and beyond."
"CyttaCOMP, is at the core of our products and is the most potent software compression codec commercially available."
"We believe our products will enable and empower the world to consume higher quality video anywhere, anytime while providing unparallelled safety and security."
"The Company is currently working to finalize the MMP (Minimum Marketable Product) version of the CyttaCOMMS software designated CyttaCOMMS 2.0 for the marketplace."
"The CyttaCARES system has reached the trial or MVP stage, however because of the sensitive nature of the technology the product will require additional work to bring it to the MMP stage, before we begin live school demonstrations."
"Cytta Labs was formed to be a next generation venture studio, and the strategic evolution of Cytta Corp into an innovation holding company focused on IP, equity ownership, and long-term value creation."
"Our inability to generate capital or raise additional funds when required will have a negative impact on our business development and financial results."

Industry Context

Cytta Corp. operates in the disruptive technology space, focusing on video compression (CyttaCOMP), incident management (CyttaCOMMS), and safety/security software (CyttaCARES). These areas are highly competitive and rapidly evolving, with increasing demand for real-time, low-latency video streaming and robust emergency response systems, particularly in public safety and educational sectors. The formation of Cytta Labs as a venture studio suggests a strategy to diversify and leverage IP in a broader innovation ecosystem, potentially seeking to incubate or acquire new technologies. The reliance on the value of Reticulate Micro stock indicates a significant tie to the performance of a related entity in the cybersecurity/ISR market.

Comparison to Industry Standards

Direct comparisons to specific comparable companies or projects are not provided in the filing.
The company's revenue is minimal, making standard industry performance benchmarks difficult to apply meaningfully.
The focus is on product development and strategic restructuring rather than market penetration or competitive results.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Material Weakness in Internal Controls	The company does not have an Audit Committee, which management views as an "utmost important entity level control." The Board of Directors acts in this capacity but lacks an independent member for necessary oversight.	June 30, 2025	Increases the risk of material misstatement of financial statements not being prevented or detected on a timely basis.
Material Weakness in Internal Controls	The company did not maintain appropriate cash controls, including failure to segregate cash handling and accounting functions, and did not require dual signatures on bank accounts.	June 30, 2025	Increases the risk of material misstatement of financial statements not being prevented or detected on a timely basis.

Related Party Transactions

**CEO Management Fees**: $45,000 for the three months and $135,000 for the nine months ended June 30, 2025.
**President and COO Management Fees**: $45,000 for the three months and $135,000 for the nine months ended June 30, 2025.
**Stock-based compensation expense, officers**: $118,158 for the three months and $365,325 for the nine months ended June 30, 2025, related to the COO's agreement (250,000 common shares per month, CYCA Option, RM Warrant).
**Office Rent and Expenses**: $8,702 for the three months and $24,613 for the nine months ended June 30, 2025, for the COO's office space.
**Related Party Liabilities**: As of June 30, 2025, the company owes $110,000 for CEO management fees, $48,040 for CEO bonus, $257,960 for stock to be issued to President and COO, and $16,371 for accounts payable to President and COO, totaling $432,371.
**Reticulate Micro (RM)**: Cytta Corp. licensed its SUPR ISR technology to RM. RM's co-founders include former Cytta Corp. officers (Mr. Collins, Mr. Chermak, Mr. Ansari). Cytta holds RM Class A Common Stock and has issued RM stock to settle convertible notes.

Stakeholder Impact

**Shareholders**: Potential for significant volatility due to reliance on marketable securities valuation. The going concern warning and need for future capital raises could lead to dilution. Product development delays may impact future revenue generation.
**Employees/Management**: Continued compensation through stock-based awards and management fees, but the overall financial health and going concern status could create uncertainty.
**Creditors**: Convertible noteholders have seen their debt converted into RM stock, reducing direct debt exposure to Cytta but shifting risk to RM's performance.
**Customers**: Delays in CyttaCOMMS 2.0 and CyttaCARES MMP versions mean customers will wait longer for fully functional enterprise-level products.

Next Steps

Finalize the MMP (Minimum Marketable Product) version of CyttaCOMMS software (CyttaCOMMS 2.0) for enterprise-level sales.
Complete additional work on the CyttaCARES system to bring it to the MMP stage for live school demonstrations.
Seek equity and/or debt financing arrangements to fund operations, capital expenditures, and working capital.
Address material weaknesses in internal controls over financial reporting, specifically regarding the Audit Committee and cash controls.

Key Dates

Date	Description
2006-05-30	Cytta Corp. incorporated in Nevada.
2022-06-22	Reticulate Micro, Inc. (RM) formed.
2022-08-09	Intellectual Property License Agreement (IPLA) signed with Reticulate Micro, Inc.
2023-01-01	Monthly fee for CEO set at $15,000.
2023-02-01	Consulting Executive Officer Agreement with SGG (COO) effective, with a three-year term.
2023-02-08	Investor paid $5,000 to acquire a warrant to purchase 2,000,000 common shares and 100,000 RM Stock shares.
2023-02-10	Warrant issued to an investor to purchase 2,000,000 common shares and 100,000 RM Stock shares in conjunction with a convertible note.
2023-03-01	Investor paid $5,000 to acquire a warrant to purchase 2,000,000 common shares and 100,000 RM Stock shares.
2023-03-03	Five convertible promissory notes (March 2023 Notes) issued for $160,000 aggregate principal. Consulting agreement with an investor for 2,000,000 common shares, options, and RM stock warrants.
2023-05-11	5,000,000 shares issued to the Company's COO as a bonus pursuant to their Consulting Agreement.
2023-05-15	Mr. Collins cancelled 1,600,000 Class B common stock shares of RM in exchange for 200,000 Class A common stock shares.
2023-07-10	15,000,000 shares issued to the Company's COO as a bonus pursuant to their Consulting Agreement.
2023-09-01	Monthly fee for President and COO increased to $15,000.
2023-09-07	5,000,000 shares issued to the Company's COO as a bonus pursuant to their Consulting Agreement.
2023-10-01	The Board of Directors appointed the COO as President. The company entered into a one-year Agreement for Board of Advisor Services with a third party for 3,000,000 shares of common stock.
2023-12-06	The company agreed to issue an additional 6,000,000 shares of common stock.
2023-12-31	A convertible promissory note of $40,000 (December 2023 Notes) matured and was extended to May 31, 2025.
2024-01-01	The company entered into a one-year Consulting Agreement with a third party for market awareness services in exchange for 3,000,000 shares of common stock.
2024-01-02	The company entered into a one-year Consulting Agreement with a third party for market awareness services in exchange for a monthly fee of $10,000 and 5,000,000 shares of common stock.
2024-01-18	5,000,000 common shares issued per the January 2, 2024, consulting agreement.
2024-03-31	Nine convertible promissory notes (March 2024 Notes) for $517,500 aggregate principal matured.
2024-04-01	The company entered an Agreement for Board of Advisor Services with a third party for 5,000,000 common shares and an RM stock warrant. The company also agreed to rent office space for the COO at $2,575 per month.
2024-04-23	The company entered an Agreement for Board of Advisor Services with a third party for 3,000,000 common shares. Another Agreement for Board of Advisor Services with a third party for 5,000,000 common shares was also entered.
2024-05-01	The company amended the October 1, 2023, agreement and agreed to issue 7,000,000 shares, of which 5,000,000 were immediately earned.
2024-05-08	3,000,000 common shares issued for the months of February 2023, through January 2024. 2,500,000 common shares issued per the April 1, 2024, agreement. 1,500,000 common shares issued per the April 23, 2024, agreement. 2,500,000 common shares issued per the April 23, 2024, agreement.
2024-05-16	2,500,000 shares of common stock issued. 5,000,000 shares issued per the May 1, 2024, amended agreement.
2024-06-30	Thirty-eight convertible promissory notes (June 2024 Notes) for $1,910,950 aggregate principal matured.
2024-09-30	Two convertible promissory notes (September 2024 Notes) for $125,000 aggregate principal issued, maturing September 30, 2025.
2025-01-23	180,000 shares of restricted common stock issued in settlement of $4,500 of accrued interest.
2025-01-27	180,000 shares of restricted common stock issued in settlement of $4,500 of accrued interest.
2025-01-30	The company began measuring its equity investment in RM at fair value; recorded the initial fair value of 2,664,609 RM shares at $9,992,284.
2025-03-03	Amended and Restated Certificate of Designation for Series A Preferred Stock filed.
2025-05-13	Cytta Labs Inc. formed as a Wyoming Corporation.
2025-06-30	End of current reporting period.
2025-07-01	CYCA Option and RM Warrant for SGG expire. Warrants from March 2023 notes expire.
2025-08-27	The company transferred 100,000 shares of RM stock in satisfaction of $100,000 principal of convertible notes (subsequent event).
2025-09-08	Beginning of period for RM stock sales (subsequent event).
2025-10-14	The company agreed to transfer 150,000 shares of RM stock to two individuals in satisfaction of Company common stock owed (subsequent event).
2025-10-15	The company issued 10,000,000 shares of common stock, valued at $220,000, to an existing shareholder (subsequent event).
2025-10-28	End of period for RM stock sales (subsequent event).
2025-10-30	Filing date of the 10-Q.

Recommendation

hold

The company's nine-month net income is a positive, but it's primarily an accounting gain from marketable securities, not from core operations, which remain unprofitable and revenue-constrained. The significant reduction in convertible debt is favorable, but the persistent "going concern" warning, product development delays for key offerings (CyttaCOMMS 2.0, CyttaCARES), and identified material weaknesses in internal controls present substantial risks. While the strategic move to Cytta Labs as a venture studio could offer long-term potential, the immediate operational challenges and reliance on external financing suggest a "Hold" recommendation. Investors should monitor progress on product commercialization, operational profitability, and capital raising efforts.

Keywords

Cytta Corp, SEC 10-Q, Quarterly Report, Financials, Software, Video Compression, CyttaCOMMS, CyttaCARES, Reticulate Micro, SaaS, Incident Management, Emergency Response, School Safety, Cybersecurity, Going Concern, Financial Technology, IP Licensing, Venture Studio

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.